Association Between Glycaemic Control and Morbi/Mortality After 5 Years of Follow-up in Type 2 Diabetic Patients

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

986 participants

Study Classification

OBSERVATIONAL

Study Start Date

2009-03-31

Study Completion Date

2021-09-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to asses the link between glycaemic balance (summarised by HBA1C LEVEL) and specific causes of death.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

HbA1c Prediction Model in Patients With Type 2 Diabetes

NCT05824286

Diabetes Mellitus, Type 2

UNKNOWN NA

Analysis of Relevant Influencing Factors of Glycemic Control in Patients With Diabetes

NCT05854862

Glycemic Control

UNKNOWN

Correlation Between Targeted HbA1c Values and Prevention of Recurrent Cardiovascular Events in Type 2 Diabetes After PCI

NCT05134129

Diabetes Mellitus Percutaneous Coronary Intervention

UNKNOWN

Association Between Uric Acid / High Density Lipoprotein Ratio and Monocyte / High Density Lipoprotein Ratio with Diabetic Complications

NCT06754813

Diabetes Mellitus

NOT_YET_RECRUITING

Relationship Between Body Weight and Glycohemoglobin

NCT00892372

Type 2 Diabetes Mellitus

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The GERODIAB study is the first prospective, longitudinal follow-up cohort study, the main aim of which is to assess the link between glycaemic balance (evaluated on the basis of HbA1c levels) and total mortality at 5 years in diabetic patients aged 70 and over, and suffering from type 2 diabetes. An extension to 10 years is considered given the innovative features of this cohort follow-up procedure.

The secondary endpoints are as follows:

* To assess the link between glycaemic balance and the mortality rate with specific causes.
* To assess the link between glycaemic balance and the onset of or change in diabetes-related complications: cardiovascular diseases, change in renal function, diabetic retinopathy, peripheral neuropathy, perforating ulcer of the foot and acute metabolic complications.
* To assess the link between glycaemic balance and nutritional status, the onset of or changes in cognitive disorders and a loss of autonomy.
* To specify the role of other cardiovascular risk factors combined with glycaemic balance, in mortality, diabetes-related complications, cognitive disorders and loss of autonomy.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Type 2 Diabetes

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patient with type 2 diabetes, aged 70 and over,
* Patient having received medicinal or non-medicinal treatment (in the case of diabetics treated with insulin, the length of time between diagnosis of diabetes and the onset of insulin therapy will be at least 2 years),
* Diabetes diagnosed for at least one year,
* Patient with autonomy defined by a score greater than or equal to 3/6 on the ADL scale,
* Patient who can be monitored during hospital or private consultations over the next 10 years,
* Patient who did not refuse to take part in the study after receiving information on the study (Patient Information Leaflet), Patients are monitored in the hospital or private sector throughout France.

Exclusion Criteria

* Patient with type 1 diabetes,
* Patient with secondary diabetes (mainly corticosteroid-induced),
* Patient with a loss of autonomy defined by a score of less than 3/6 on the ADL scale,
* Patient who cannot be monitored in the months or years to come,
* Patient in an acute situation (transient exclusion criterion),
* Patient expressing their refusal to participate in the study.

Minimum Eligible Age

70 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No